183 related articles for article (PubMed ID: 25368259)
21. Targeting the invasive phenotype of cisplatin-resistant non-small cell lung cancer cells by a novel histone deacetylase inhibitor.
Zuco V; Cassinelli G; Cossa G; Gatti L; Favini E; Tortoreto M; Cominetti D; Scanziani E; Castiglioni V; Cincinelli R; Giannini G; Zunino F; Zaffaroni N; Lanzi C; Perego P
Biochem Pharmacol; 2015 Mar; 94(2):79-90. PubMed ID: 25600908
[TBL] [Abstract][Full Text] [Related]
22. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study.
Zatloukal P; Petruzelka L; Zemanova M; Havel L; Janku F; Judas L; Kubik A; Krepela E; Fiala P; Pecen L
Lung Cancer; 2004 Oct; 46(1):87-98. PubMed ID: 15364136
[TBL] [Abstract][Full Text] [Related]
23. Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma.
Carter CA; Chen C; Brink C; Vincent P; Maxuitenko YY; Gilbert KS; Waud WR; Zhang X
Cancer Chemother Pharmacol; 2007 Feb; 59(2):183-95. PubMed ID: 16724239
[TBL] [Abstract][Full Text] [Related]
24. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
Ramlau R; Zatloukal P; Jassem J; Schwarzenberger P; Orlov SV; Gottfried M; Pereira JR; Temperley G; Negro-Vilar R; Rahal S; Zhang JK; Negro-Vilar A; Dziewanowska ZE
J Clin Oncol; 2008 Apr; 26(11):1886-92. PubMed ID: 18398154
[TBL] [Abstract][Full Text] [Related]
25. Phase I study of concurrent high-dose three-dimensional conformal radiotherapy with chemotherapy using cisplatin and vinorelbine for unresectable stage III non-small-cell lung cancer.
Sekine I; Sumi M; Ito Y; Horinouchi H; Nokihara H; Yamamoto N; Kunitoh H; Ohe Y; Kubota K; Tamura T
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):953-9. PubMed ID: 21377282
[TBL] [Abstract][Full Text] [Related]
26. A small molecule inhibitor of XIAP induces apoptosis and synergises with vinorelbine and cisplatin in NSCLC.
Dean EJ; Ward T; Pinilla C; Houghten R; Welsh K; Makin G; Ranson M; Dive C
Br J Cancer; 2010 Jan; 102(1):97-103. PubMed ID: 19904270
[TBL] [Abstract][Full Text] [Related]
27. Effect of histone deacetylase inhibitors trichostatin A and valproic acid on etoposide-induced apoptosis in leukemia cells.
Jasek E; Lis GJ; Jasinska M; Jurkowska H; Litwin JA
Anticancer Res; 2012 Jul; 32(7):2791-9. PubMed ID: 22753739
[TBL] [Abstract][Full Text] [Related]
28. Treatment of small cell lung cancer with TRA-8 in combination with cisplatin and radiation.
Bonner JA; Willey CD; Yang ES; Dobelbower MC; Sanford LL; Bright SJ; Buchsbaum DJ; Raisch KP
Radiother Oncol; 2011 Oct; 101(1):183-9. PubMed ID: 21722984
[TBL] [Abstract][Full Text] [Related]
29. Valproic acid, an anti-epileptic drug and a histone deacetylase inhibitor, in combination with proteasome inhibitors exerts antiproliferative, pro-apoptotic and chemosensitizing effects in human colorectal cancer cells: underlying molecular mechanisms.
Abaza MS; Bahman AM; Al-Attiyah RJ
Int J Mol Med; 2014 Aug; 34(2):513-32. PubMed ID: 24899129
[TBL] [Abstract][Full Text] [Related]
30. Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small-cell lung cancer.
Xie CY; Xu YP; Jin W; Lou LG
Anticancer Drugs; 2012 Aug; 23(7):698-705. PubMed ID: 22441567
[TBL] [Abstract][Full Text] [Related]
31. Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer.
Yasuda H; Yamaya M; Nakayama K; Sasaki T; Ebihara S; Kanda A; Asada M; Inoue D; Suzuki T; Okazaki T; Takahashi H; Yoshida M; Kaneta T; Ishizawa K; Yamanda S; Tomita N; Yamasaki M; Kikuchi A; Kubo H; Sasaki H
J Clin Oncol; 2006 Feb; 24(4):688-94. PubMed ID: 16446342
[TBL] [Abstract][Full Text] [Related]
32. Combined Effects of Suberoylanilide Hydroxamic Acid and Cisplatin on Radiation Sensitivity and Cancer Cell Invasion in Non-Small Cell Lung Cancer.
Feng J; Zhang S; Wu K; Wang B; Wong JY; Jiang H; Xu R; Ying L; Huang H; Zheng X; Chen X; Ma S
Mol Cancer Ther; 2016 May; 15(5):842-53. PubMed ID: 26839308
[TBL] [Abstract][Full Text] [Related]
33. The novel thymidylate synthase inhibitor trifluorothymidine (TFT) and TRAIL synergistically eradicate non-small cell lung cancer cells.
Azijli K; van Roosmalen IA; Smit J; Pillai S; Fukushima M; de Jong S; Peters GJ; Bijnsdorp IV; Kruyt FA
Cancer Chemother Pharmacol; 2014 Jun; 73(6):1273-83. PubMed ID: 24744163
[TBL] [Abstract][Full Text] [Related]
34. A phase II randomized study of vinorelbine alone or with cisplatin against chemo-naïve inoperable non-small cell lung cancer in the elderly.
Chen YM; Perng RP; Shih JF; Whang-Peng J
Lung Cancer; 2008 Aug; 61(2):214-9. PubMed ID: 18243407
[TBL] [Abstract][Full Text] [Related]
35. Isorhamnetin flavonoid synergistically enhances the anticancer activity and apoptosis induction by cis-platin and carboplatin in non-small cell lung carcinoma (NSCLC).
Zhang BY; Wang YM; Gong H; Zhao H; Lv XY; Yuan GH; Han SR
Int J Clin Exp Pathol; 2015; 8(1):25-37. PubMed ID: 25755690
[TBL] [Abstract][Full Text] [Related]
36. Emodin enhances cisplatin-induced cytotoxicity via down-regulation of ERCC1 and inactivation of ERK1/2.
Ko JC; Su YJ; Lin ST; Jhan JY; Ciou SC; Cheng CM; Chiu YF; Kuo YH; Tsai MS; Lin YW
Lung Cancer; 2010 Aug; 69(2):155-64. PubMed ID: 19962780
[TBL] [Abstract][Full Text] [Related]
37. A histone deacetylase inhibitor YCW1 with antitumor and antimetastasis properties enhances cisplatin activity against non-small cell lung cancer in preclinical studies.
Huang WJ; Tang YA; Chen MY; Wang YJ; Hu FH; Wang TW; Chao SW; Chiu HW; Yeh YL; Chang HY; Juan HF; Lin P; Wang YC
Cancer Lett; 2014 Apr; 346(1):84-93. PubMed ID: 24355296
[TBL] [Abstract][Full Text] [Related]
38. Additive Interaction of Cisplatin and Histone Deacetylase Inhibitors Combined Treatment in Rhabdomyosarcoma Cells - An Isobolographic Analysis.
Jarząb A; Łuszczki JJ; Guz M; Gumbarewicz E; Polberg K; Stepulak A
Anticancer Res; 2017 Mar; 37(3):1067-1074. PubMed ID: 28314266
[TBL] [Abstract][Full Text] [Related]
39. Sodium valproate potentiates staurosporine-induced apoptosis in neuroblastoma cells via Akt/survivin independently of HDAC inhibition.
Shah RD; Jagtap JC; Mruthyunjaya S; Shelke GV; Pujari R; Das G; Shastry P
J Cell Biochem; 2013 Apr; 114(4):854-63. PubMed ID: 23097134
[TBL] [Abstract][Full Text] [Related]
40. A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of non-small cell lung cancer: an expanded analysis.
Le Chevalier T; Pujol JL; Douillard JY; Alberola V; Monnier A; Riviere A; Lianes P; Chomy P; Cigolari S; Besson F
Semin Oncol; 1994 Oct; 21(5 Suppl 10):28-33; discussion 33-4. PubMed ID: 7973766
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]